Trial
NCT02609048
Study to Evaluate the Effects of Two Doses of Seladelpar (MBX-8025) in Subjects With Primary Biliary Cirrhosis (PBC)
Phase IITERMINATEDOTHER/UNKNOWNConfidence: LOW
Sponsor
Gilead Sciences
Collaborators
—
Condition
Primary Biliary Cirrhosis (PBC)
Intervention
Placebo Comparator
Why stopped
Study stopped early after review of safety and efficacy demonstrated efficacy proof-of-concept and need for dose reduction.
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2025-02-25